stockrow
Friday 6 November 2026
Export TKNO’s income statement to Excel — free account
Alpha Teknova, Inc.
TKNO Healthcare Drug Manufacturers Specialty & Generic
Alpha Teknova, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.5 million, up 7.35% from fiscal 2024.
- Revenue
- +21.5%
- EPS
- +25.0%
- Free cash flow
- +40.9%
- Total debt
- +1.48%
Quarter to September 2026, against a year earlier
7.76
0.12
−1.52%
Follow TKNO
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 4 | 4 | 5 |
+8 more TTM periods Free account |
| (24.12%) | (24.19%) | (23.92%) | (22.83%) | ||
| (15.79%) | (16.25%) | (16.15%) | (15.52%) | ||
ROIC |
(16.60%) | (16.93%) | (16.90%) | (17.52%) | |
Return on Tangible Assets |
(26.20%) | (26.51%) | (26.29%) | (25.12%) | |
Average Days of Receivables |
46.23 | 45.17 | 49.53 | 41.60 | |
Free Cash Flow per Share |
(0.12) | (0.14) | (0.17) | (0.18) | |
Free Cash Flow |
(6.38) | (7.35) | (9.06) | (9.79) | |
Capital Expenditures |
(0.81) | (1.08) | (1.16) | (1.15) | |
| Other line items | |||||
Cash ROIC |
(7.12%) | (7.88%) | (9.45%) | (9.49%) | |
Accounts Receivable Turnover |
8.39 | 8.29 | 7.41 | 9.08 | |
Accounts Payable Turnover |
20.17 | 21.64 | 17.39 | 24.58 | |
Inventory Turnover |
4.06 | 3.94 | 4.10 | 3.91 | |
Average Days of Payables |
22.65 | 18.36 | 21.41 | 18.57 | |
Days of Inventory on Hand |
93.43 | 88.26 | 90.96 | 95.08 | |
Tax Rate |
0.00 | 0.01 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
4.93% | 5.10% | 5.39% | 5.42% | |
Selling, General and Administrative Expense of Revenue |
61.65% | 63.06% | 64.89% | 66.81% | |
Share Based Compensation of Revenue |
5.89% | 6.74% | 7.83% | 8.46% | |
Interest Coverage |
(15.94) | (18.14) | (20.78) | (23.91) | |
Operating CF/Net income |
0.35 | 0.37 | 0.46 | 0.50 | |
Depreciation/Fixed assets |
0.00 | 0.16 | 0.15 | 0.14 | |
Capex/Depreciation |
0.00 | (0.18) | (0.19) | (0.19) | |
Revenue per Share |
0.86 | 0.81 | 0.78 | 0.76 | |
Operating CF per Share |
(0.10) | (0.12) | (0.15) | (0.16) | |
Capex per Share |
(0.02) | (0.02) | (0.02) | (0.02) | |
Capex to Sales |
0.02 | 0.02 | 0.03 | 0.03 |
Columns are period end dates · fundamentals updated 5 Nov 2026